US regulatory status: approved.
pharma · Opioid Use Disorder · Opioid Dependence
Indivior Pty
Indivior Pty Ltd
Indivior Pty drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- ., Richmond, VA, US
- Employees
- 967
- Programs
- 39
- Drugs
- 19
- Patents
- 34
Indivior Pty pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Indivior Pty drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
buprenorphine
Nervous system (N07)US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
Development asset linked to Indivior Pty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Indivior Pty in public FDA and regional records.
-
Development asset linked to Indivior Pty in public FDA and regional records.
-
Development asset linked to Indivior Pty in public FDA and regional records.
-
Development asset linked to Indivior Pty in public FDA and regional records.
-
Development asset linked to Indivior Pty in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta antagonist
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
risperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
Development asset linked to Indivior Pty in public FDA and regional records.
-
Development asset linked to Indivior Pty in public FDA and regional records.